Dr. Jensen Yeung

Dermatologist, Toronto, ON

Dr. Jensen Yeung obtained his Doctor of Medicine degree from McMaster University in 2001. In the same year, he began his dermatology residency training at the University of Toronto. During his residency training, he spent 6 months in Australia, New York, and Boston gaining clinical experience and acquiring newest knowledge in the field of melanoma and dermscopy from leading experts. In 2005, he was selected by the residency program as the co-chief resident for the year. Having obtained his board certification from the Royal College of Physicians and Surgeons of Canada in 2006, he joined the Faculty of Dermatology at the University of Toronto, where he ran teaching clinics at both Women’s College Hospital and the Sunnybrook Health Sciences Centre. In 2007, he was promoted to the position of medical director for the RKS Dermatology Program at Women’s College Hospital, where he ran a melanoma, psoriasis, and General Dermatology clinic. In 2013, he switched from RKS to PERC and took on the new role as the medical director of PERC (phototherapy education and research centre) where he runs a weekly psoriasis/phototherapy clinic. In 2014, he and Dr. Dana Jerome started a monthly combined psoriasis/psoriatic arthritis clinic at PERC. In 2011, he joined Dr. Kim Papp’s research facility in Waterloo and has participated in close to 200 phase 1 to 4 clinical trials. He has also supervised and mentored many research students and residents, which has led to around 100 peer reviewed publications. He is an associate editor at JCMS and Canadian Dermatology Today. He has received a number of teaching awards including the best resident teacher award in 2005, the 2008 Women’s College Hospital Department of Medicine Postgraduate Teaching Award and the 2009 University of Toronto Dermatology Postgraduate Program Staff Teaching Award.

4:00 PM - 6:00 PM Sun Pharma Advisory Board

Thursday NOV 11, 2021

Ilumya™ is here for your patients, long SUNny days ahead

4:35 PM - 5:35 PM Bausch Open Session

Friday NOV 12, 2021

Treating moderate-to-severe plaque psoriasis to target: new and old concepts for topical and biologic therapies

Treat-to-target (T2T) refers to a clinical framework for managing chronic diseases that sets standards for assessing treatment goals and suggests treatment strategies if targets are not achieved. T2T recommendations in moderate-to-severe plaque psoriasis have been published by expert groups from around the world. In these, treatment target is usually defined by a single severity measure, targets vary between consensus groups, and there are few recommendations for modifying treatment if target is not achieved. In this symposium, we present a multi-dimensional, criteria-based, T2T model developed by Canadian dermatologists managing moderate-to-severe plaque psoriasis. Treatment modification strategies will be presented and discussed with a focus on optimizing or switching biologic treatments. As topical treatments as mainstays in managing psoriasis, their role within a T2T model will be discussed with consideration given to long-term data from recently published studies.



  • Introduce a Canadian criteria-based model for treatment targets in plaque psoriasis.
  • Review evidence supporting treatment strategies for when target is not achieved, with a focus on switching biologics.
  • Consider a treat-to-target approach in the early management of plaque psoriasis and critically appraise new clinical data on the long-term management of plaque psoriasis using topical treatments
2:25 PM - 3:25 PM Sun Pharma Open Session

Saturday NOV 13, 2021

Illumya™ is here for your patients, long SUNny days ahead

Following a presentation of tildrakizumab efficacy and safety data, participants will engage in open discussion to discuss how tildrakizumab may fill an unmet need in moderate-to-severe PsO, its place in treatment compared to IL-23 inhibitors, and best clinical practice in the management of PsO patients.


  1. Understand & gain insights into how Canadian dermatologists currently manage patients with moderate-to-severe psoriasis;
  2. Identify how tildrakizumab can fulfill an unmet need with Canadian dermatologists;
  3. Share clinical experience and best practices on what outcome measures could facilitate clinical decisions in the management of patients with psoriasis.